Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia

Brijesh Arora, Ruben A. Mesa, Ayalew Tefferi

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest in hematological malignancies. This particular information has encouraged the therapeutic use of anti-angiogenic drugs in MMM. In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM.

Original languageEnglish (US)
Pages (from-to)2373-2386
Number of pages14
JournalLeukemia and Lymphoma
Issue number12
StatePublished - Dec 2004


  • Agnogenic myeloid metaplasia
  • Angiogenesis
  • Anti-antigenesis treatment
  • MPD
  • Myelofibrosis
  • Myelofibrosis therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia'. Together they form a unique fingerprint.

Cite this